Skip to main content

Table 4 Efficacy of first-line anti-malarials in three therapeutic efficacy monitoring sites in Angola, 2017

From: Efficacy and safety of artemether–lumefantrine, artesunate–amodiaquine, and dihydroartemisinin–piperaquine for the treatment of uncomplicated Plasmodium falciparum malaria in three provinces in Angola, 2017

  Efficacy (95% confidence intervals)
Benguela Zaire Lunda Sul
DPb ASAQa ALa ASAQa ALa DPb
Uncorrected
 Per-protocol day 28 100 (95–100) 99 (94–100) 92.8 (85–97) 82.2 (72–89) 90.1 (82–95) 100 (95–100)
 Per-protocol day 42 94.6 (87–98) 100 (95–100)
 Kaplan–Meier estimate day 28 100 (100–100) 98.9 (97–100) 92.7 (88–98) 82.1 (75–90) 90.1 (84–96) 100 (100–100)
 Kaplan–Meier estimate day 42 94.6 (90–99) 100 (100–100)
PCR-corrected
 Per-protocol day 28 100 (97–100) 100 (97–100) 95.5 (89–98) 93 (85–97) 96.4 (90–99) 100 (96–100)
 Per-protocol day 42 100 (96–100) 100 (96–100)
 Kaplan–Meier estimate day 28 100 100 (97–100) 95.5 (91–100) 93.3 (88–99) 96.5 (93–100) 100
 Kaplan–Meier estimate day 42 100 (96–100) 100
  1. Per-protocol efficacy defined as proportion adequate clinical and parasitological response, Kaplan–Meier estimate calculated from estimate of survival function
  2. AL artemether–lumefantrine, ASAQ artesunate–amodiaquine, DP dihydroartemisinin–piperaquine
  3. a28-day follow up
  4. b42-day follow up